Inovio Pharmaceuticals, Inc., together with its subsidiaries, engages in the discovery, development, and delivery of DNA vaccines with a focus on cancers and infectious diseases. The company’s SynCon technology enables the design of DNA-based vaccines capable of providing cross-protection against new, unmatched strains of pathogens, such as influenza. Its electroporation DNA delivery technology uses controlled electrical pulses to enhance cellular DNA vaccine uptake. The company’s clinical programs include human papillomavirus/cervical cancer (therapeutic), avian influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), and hepatitis C virus and human immunodeficiency virus vaccines. It is also advancing preclinical research and clinical development for a seasonal/pandemic influenza vaccine, as well as preclinical work for other products, including malaria and prostate cancer vaccines. The company was formerly known as Inovio Biomedical Corporation and changed its name to Inovio Pharmaceuticals, Inc. in May 2010. Inovio Pharmaceuticals, Inc. was founded in 1983 and is headquartered in Blue Bell, Pennsylvania.

The Chain.io supply chain integration platform represents a new approach to an age-old supply chain question. “How do we make all of these systems and people work together?” Our cloud-based platform solves these problems using an open application programming interface (API), developer friendly tools, an expertly developed data model, and event driven behaviors to make connecting and coordinating systems and people easier than ever before. The platform uses complex, next generation technologies like data graphs, and Artificial Intelligence without all of the heavy lifting involved in most supply chain integration projects.